Literature DB >> 7703312

Variation in the expression of human immunodeficiency virus RNA and cytokine mRNA in rectal mucosa during the progression of infection.

S Reka1, M L Garro, D P Kotler.   

Abstract

Previous studies demonstrated that mucosal HIV p24 antigen content varied during the progression of HIV infection. In this study, expression of HIV RNA and mRNA of selected cytokines was examined in rectal mucosa from HIV-infected individuals. Rectal biopsies from 27 subjects were studied: 7 with CD4 counts > 500/mm3 (early), 11 with CD4 < 500 (intermediate), and 9 with AIDS (late), plus 4 HIV-seronegative controls. RNA in situ hybridization was performed using 35S-labeled riboprobes of HIV, TNF-alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-10, INF-alpha, IFN-gamma, and TGF-beta. HIV RNA was detected more frequently in the intermediate group than in the other groups (p < 0.005). Cytokine mRNA expression also varied during disease progression. The expression of IFN-alpha, IFN-gamma, and TGF-beta mRNA was most prevalent early in the disease; peak expression of IL-4, IL-5, IL-6, and IL-10 was seen during the intermediate stage, and peak expression of TNF-alpha and IL-1 beta mRNA were seen in AIDS patients. HIV RNA and cytokine mRNA expression vary during HIV disease progression. HIV RNA expression is greatest in the intermediate stage of the disease. The pattern of cytokine mRNA expression suggests predominant cell-mediated immunity under basal conditions and early in the disease, generalized cytokine activation in its middle phase, and proinflammatory cytokine activation in AIDS patients. Cytokine modulation of HIV expression in rectal mucosa in vivo may occur and have pathogenic importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7703312

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  7 in total

Review 1.  HIV1 and the gut in the era of highly active antiretroviral therapy.

Authors:  Esteban C Nannini; Pablo C Okhuysen
Journal:  Curr Gastroenterol Rep       Date:  2002-10

2.  Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection.

Authors:  Pamela P Gumbi; Nonhlanhla N Nkwanyana; Alfred Bere; Wendy A Burgers; Clive M Gray; Anna-Lise Williamson; Margaret Hoffman; David Coetzee; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

3.  Expression of tumor necrosis factor alpha and interleukin 1 beta in jejuna of volunteers after experimental challenge with Cryptosporidium parvum correlates with exposure but not with symptoms.

Authors:  P Robinson; P C Okhuysen; C L Chappell; D E Lewis; I Shahab; A Janecki; A C White
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy.

Authors:  Hubert Schulbin; Hagen Bode; Hartmut Stocker; Wolfgang Schmidt; Thomas Zippel; Christoph Loddenkemper; Elisabeth Engelmann; Hans-Jörg Epple; Keikawus Arastéh; Martin Zeitz; Reiner Ullrich
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

Review 5.  HIV pathogenesis: the host.

Authors:  A A Lackner; Michael M Lederman; Benigno Rodriguez
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

Review 6.  The gastrointestinal tract and AIDS pathogenesis.

Authors:  Andrew A Lackner; Mahesh Mohan; Ronald S Veazey
Journal:  Gastroenterology       Date:  2009-05       Impact factor: 22.682

7.  CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide.

Authors:  Edana Cassol; Theresa Rossouw; Susan Malfeld; Phetole Mahasha; Tomas Slavik; Chris Seebregts; Robert Bond; Johannie du Plessis; Carl Janssen; Tania Roskams; Frederik Nevens; Massimo Alfano; Guido Poli; Schalk W van der Merwe
Journal:  BMC Infect Dis       Date:  2015-10-17       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.